59215-34-8

Basic information

• Product Name: Pyrimidine, 2-(3-methyl-1-piperazinyl)- (9CI)
• Synonyms: Pyrimidine, 2-(3-methyl-1-piperazinyl)- (9CI);2-(3-METHYLPIPERAZIN-1-YL)PYRIMIDINE
• CAS NO: 59215-34-8
• Molecular Formula: C₉H₁₄N₄
• Molecular Weight: 178.23426
• Product Categories: PIPERIDINE
• Mol File: 59215-34-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Pyrimidine, 2-(3-methyl-1-piperazinyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrimidine, 2-(3-methyl-1-piperazinyl)- (9CI)(59215-34-8)
• EPA Substance Registry System: Pyrimidine, 2-(3-methyl-1-piperazinyl)- (9CI)(59215-34-8)

Safety Data

• Hazardous Substances Data: 59215-34-8(Hazardous Substances Data)

Upstream product

• 1722-12-9 2-chloropyrimidine 
• 109-07-9 (RS)-2-methylpiperazine 
• 120737-78-2 tert-butyl 2-methylpiperazine-1-carboxylate 
• 1420993-14-1 2-methyl-4-pyrimidin-2-yl-piperazine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 676596-26-2 C₁₈H₁₈N₄O 

Relevant articles and documents

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

Synthesis of 1,4-disubstituted 2-methylpiperazine derivatives, new 5-HT1A receptor ligands

Preparation of some new 1,4-substituted 2-methylpiperazine derivatives is reported. The influence of structural modifications on their affinity to 5-HT1A receptors is discussed. Compounds were synthesized by the reaction of 2-methylpiperazine with 2-chloropyrimidine or 2-chloroquinoline followed by condensation with 1,4-dibromobutane. The resulting quaternary ammonium salts after the reaction with an imide gave the respective final products.